Following on from information provided to NICE by the company in March 2020, the appraisal of Etirinotecan pegol for treating breast cancer with brain metastases [ID881] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 881 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 23 November 2022 | Discontinued. Following on from information provided to NICE by the company in March 2020, the appraisal of Etirinotecan pegol for treating breast cancer with brain metastases [ID881] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 21 April 2020 | The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of etirinotecan pegol for treating breast cancer with brain metastases. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 25 July 2017 | Suspended. The Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for etirinotecan pegol intended for the treatment of advanced breast cancer with brain metastases. Consequently the first appraisal committee discussion of this topic, has been cancelled. We will continue to monitor any developments and will update interested parties if the situation changes. |
| 18 August 2016 | Invitation to participate |
| 02 June 2016 | Draft scope documents |
| 13 May 2016 | Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual